CMO, discussed a presentation from Maui Derm 2026 in which he spoke about therapies in the pipeline for psoriasis.

Icotrokinra, a novel oral interleukin (IL)-23 inhibitor, provided a level of response in moderate-to-severe plaque psoriasis that is similar to that previously reported with injectable biologics, ...

Oral roflumilast showed significant efficacy in reducing psoriasis severity, with 63% achieving PASI less than 5 by week 24. The study reported mild gastrointestinal symptoms but no serious adverse ...

ORLANDO, Fla. — Adults with moderate to severe plaque psoriasis taking the novel oral drug icotrokinra had significant improvement starting at week 16, with increased response rates continuing through ...

Improved targeting of the molecular drivers of psoriasis has paved the way for new oral therapies that offer the potential for major responses in a majority of patients. Identification of better ...

Psoriasis significantly impacts quality of life, affecting sleep and mental health, with a high prevalence of comorbidities. The ENCOMPASS study surveyed patients and dermatologists, highlighting ...

Icotrokinra, a targeted oral peptide that selectively binds the interleukin-23 receptor, is under investigation for the treatment of plaque psoriasis. We conducted a phase 3, double-blind, randomized, ...

Any practitioner who cares for patients with psoriasis should be familiar with and make use of systemic therapies. These medications are clearly indicated for patients who have diffuse disease where ...